Amgen's IMDELLTRA Combination Therapy Shows Significant Survival Benefit in First-Line SCLC — Amgen Inc.

Event summary

Amgen's Phase 3 DeLLphi-305 study met its primary endpoint, showing statistically significant and clinically meaningful improvement in overall survival for IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone in first-line extensive stage small cell lung cancer (ES-SCLC).
The study also demonstrated significant improvements in progression-free survival (PFS) and objective response rate (ORR).
The safety profile of the combination therapy was consistent with the known safety profiles of the individual medicines, with no new or unexpected safety signals identified.
Amgen plans to present detailed data from DeLLphi-305 at an upcoming international medical congress and share it with regulatory authorities.

The big picture

Amgen's landmark results position IMDELLTRA as a potential game-changer in the treatment of extensive stage small cell lung cancer, a notoriously aggressive and difficult-to-treat form of lung cancer. The positive data from the DeLLphi-305 study underscore the growing importance of combination therapies in oncology, particularly those involving bispecific T-cell engagers (BiTE®) and immune checkpoint inhibitors. This development comes at a time when the biotech industry is increasingly focused on improving outcomes for patients with limited treatment options.

What we're watching

Regulatory Approval: Whether the positive data from DeLLphi-305 will expedite regulatory approval for IMDELLTRA in combination with durvalumab for first-line ES-SCLC.
Commercialization Strategy: How Amgen plans to commercialize this combination therapy and integrate it into existing treatment paradigms for SCLC.
Competitive Landscape: The potential impact of these results on the competitive landscape for SCLC treatments, particularly in the first-line setting.